ELV Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -7.59%, SMA50 -5.28%, SMA200 -3.78%). The stock’s 14-day RSI is 39.23 (weak momentum), while the ATR of 12.66 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -27.57% below its high and over 21.39% above its low. Average 10-day trading volume of 2.66 million shares is significantly above the 3-month average of 1.57 million, indicating heightened recent market interest.

Elevance Health Inc. has 225.18 million shares outstanding. The public float is 224.66 million shares, elevated short interest at 1.26% of float. This equals 2.84 million shares. The short ratio is 0.92 days. Institutional investors hold 93.41% of the float. Insiders own 0.17%. BOUDREAUX GAIL holds 144.85 thousand shares, Gallina John E has 54.32 thousand shares and MCCARTHY GLORIA M has 51.44 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Elevance Health Inc. (NYSE:ELV) closed at $332.25 USD, losing -$8.35 (-2.45%) from the previous close of $340.60. The stock is currently mid-range between its 52-week high and low $273.71 and $458.75. With a market capitalization of about $73.84 billion, Elevance Health Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.50). Key stats such as the average daily volume over the past year has been around 1.63 million shares, in line with its 52-week average. Headquartered in Indianapolis, IN, Elevance Health Inc. operates in the Healthcare sector and the Medical - Healthcare Plans industry. Led by CEO Gail Koziara Boudreaux, the company employs approximately 104,200 people and listed since October 30, 2001. Elevance Health Inc. operates as a health benefits company.

Elevance Health Inc. last paid a dividend of 6.84 per share, this equals a trailing yield of roughly 1.15%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.16 thousand. This means the shares are trading below this model’s fair value.

Elevance Health Inc. generated EPS of $25.11 over the past year. Five-year average earnings growth is 6.99%. Wall Street analysts project EPS growth of 5.12% annually over the next five years. The latest quarter delivered EPS of $6.03. The next quarter is forecast at $10.57. Next year's EPS is expected at $12.19. Analyst sentiment is bullish. Analyst rating data shows there are 22 Strong Buy ratings, 12 Buy ratings, 7 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $518.00 to $297.00. The high target offers 55.91% upside. The low target suggests -10.61% downside. The mean target is $392.20. This offers 18.04% upside. Elevance Health Inc. earnings surprise history is a mixed track record. The quarter that ended October 21, 2025, missed forecasts by 22.31%. The prior quarter beat by -0.79%. Over the last six quarters, Apple has recorded several small beats. These include 1.2% in July 17, 2024.

Elevance Health Inc. trades at a P/E ratio of 13.04, slightly below the S&P 500 average, with a price-to-sales ratio of 0.37 and a price-to-book ratio of 1.68 suggesting the stock is closer to book value. The P/FCF stands at 23.32, also above market averages.

Elevance Health Inc. (NYSE:ELV) shares are flat 4.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Elevance Health Inc. trading at a premium to the broader market with a P/E of 13.04. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $472.37, suggesting 42.17% upside. Our AI forecast model points to short-term weakness (-6.34% over two weeks), a medium-term rise (68.08% over three months), and a longer-term loss (-12.41% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Elevance Health Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.34%, with price expected at $311.17 by February 19, 2026, within a range of $300.14 to $323.26 3-Month Outlook: Projected rise of 68.08%, reaching $558.45 by May 06, 2026, with a range of $532.79 to $588.48. 1-Year Outlook: Projected loss of -12.41%, with price at $291.03 by February 05, 2027, within a range of $273.14 to $311.06.